Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/UBS keeps GSK neutral, eyes CEO's strategy update over Q2 results and pipeline plans
GSK
$52.21
-$0.57 -1.08%

UBS keeps GSK neutral, eyes CEO's strategy update over Q2 results and pipeline plans

Market News
13 Jul 2026
Proactive Investors - Finance
View Source
Neutral
pluang ai news

UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and forecasts. Key points include GSK's pipeline reprioritization after acquiring Nuvalent, weakness in respiratory treatments in the US, and a court trial over cancer drug rights. UBS forecasts modest revenue growth below company guidance and awaits clarity on the strategic direction at the capital markets day on July 28.

More News (GSK)

UBS keeps GSK neutral, eyes CEO's strategy update and pipeline reprioritization after Nuvalent deal

UBS keeps GSK neutral, eyes CEO's strategy update and pipeline reprioritization after Nuvalent deal

UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...

Market News
Neutral
7 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App